Financial Performance - The company reported a total revenue of RMB 105,040,000 for the year 2020, with a cash dividend of RMB 3 per 10 shares distributed to shareholders[5]. - The company's operating revenue for 2020 was ¥443,076,112.54, representing a 16.71% increase compared to ¥379,647,097.53 in 2019[17]. - The net profit attributable to shareholders for 2020 was ¥96,958,582.41, a decrease of 5.26% from ¥102,343,469.80 in 2019[18]. - The net profit after deducting non-recurring gains and losses was ¥89,757,215.36, which is a 6.17% increase from ¥84,541,753.95 in 2019[18]. - The total assets at the end of 2020 were ¥827,239,473.77, reflecting a 9.19% increase from ¥757,642,068.05 at the end of 2019[18]. - The net assets attributable to shareholders increased by 9.58% to ¥739,520,007.37 at the end of 2020 from ¥674,881,424.96 at the end of 2019[18]. - The basic earnings per share for 2020 was ¥0.9231, down 5.26% from ¥0.9743 in 2019[18]. - The cash flow from operating activities for 2020 was ¥83,339,499.34, an increase of 7.41% compared to ¥77,590,761.60 in 2019[18]. - The company achieved total revenue of 443.08 million yuan, a year-on-year increase of 16.71%, while net profit attributable to shareholders decreased by 5.26% to 96.96 million yuan[86]. - The company achieved a gross profit margin of 57.44% in 2020, down 13.05% from the previous year[116]. Business Strategy and Market Position - The company is focused on expanding its market presence and enhancing its product offerings in the medical device sector[9]. - The company aims to become a leader in the comfort medical device sector, focusing on pain management and nasal airway management as core business lines[28]. - The company has established partnerships with major medical institutions to create model hospitals for painless treatment, aiming to enhance its brand influence[30]. - The company is leveraging national policies that promote the development of medical devices, particularly in pain management and nasal airway care, to enhance its market position[52]. - The company plans to expand its product offerings in the sleep monitoring and treatment market, focusing on integrated solutions for sleep apnea and related disorders[44]. - The company aims to accelerate the industrial transformation of new technologies to keep pace with market demands and industry trends[173]. - The company plans to enhance market development efforts and improve operational efficiency[189]. Research and Development - The company is committed to enhancing its research and development capabilities through collaboration with research institutions and medical units to maintain its technological leadership in the industry[173]. - The company invested CNY 23.55 million in R&D, focusing on pain management and nasal airway management medical devices[102]. - The company is developing a pain assessment algorithm based on electrophysiology, currently in the modeling analysis phase[124]. - The company is actively pursuing innovation in medical devices, with multiple products under development aimed at improving patient outcomes[106]. - The company has a dedicated R&D team that collaborates with renowned academic institutions[78]. Product Development and Offerings - The pain management business includes the development of high-precision intelligent microcomputer infusion pumps and wireless pain management systems, targeting post-operative, labor, and cancer pain management[30]. - The iPainfree™ wireless pain management system offers features such as real-time PCA monitoring and pain data management, enhancing patient care and reducing medical errors[33]. - The company has developed the iPainfree™ obstetric pain management information system, filling a gap in the market for comprehensive solutions in labor pain management[35]. - The company is expanding its product ecosystem in pain management and nasal airway management, with a focus on disease segmentation and management[29]. - The company is developing a third-class programmable pulse infusion pump aimed at precise and quantitative control of drug infusion for pain management and childbirth[106]. - The company is working on a chemotherapy system device with high precision and smart alarm features, currently in product registration inspection[125]. Financial Management and Investments - The company plans to distribute a cash dividend of 4 RMB per 10 shares, totaling 32,320,000 RMB, and will also increase its capital stock by 3 shares for every 10 shares held, resulting in a total capital increase of 24,240,000 shares[179]. - The company has committed to invest CNY 26,293,000.00 in various projects, with a cumulative investment of CNY 6,424,260.00, representing 20.59% of the total[154]. - The company has established a fundraising management system to enhance the efficiency and effectiveness of fund usage[152]. - The company has made significant equity investments totaling ¥114,830,000.00 during the reporting period[145]. - The company has established a mechanism for investor returns to enhance shareholder confidence[189]. Quality Control and Compliance - The company emphasizes the importance of adhering to quality management systems to mitigate quality control risks associated with its medical devices[174]. - The company has implemented strict quality control measures across procurement, production, transportation, and storage to ensure product safety and effectiveness[175]. - The company has established a comprehensive quality control system covering all aspects from R&D to after-sales service, achieving ISO9001 and ISO13485 certifications[80]. - The company has no current or future plans to engage in any competing businesses with its subsidiaries[189]. Market Trends and Opportunities - The per capita consumption ratio of drugs and medical devices in China is significantly lower than the global average, indicating substantial growth potential in the medical device market[51]. - The current postpartum analgesia rate in China is around 15%, compared to over 80% in Western countries, indicating a substantial market opportunity for pain management solutions[56]. - The cancer pain management market is expanding, with approximately 25% of newly diagnosed cancer patients experiencing pain, and up to 60%-80% of late-stage cancer patients suffering from pain[57]. - The market for pain management and nasal airway management medical devices is in its early stages but has significant growth potential due to increasing demand for medical devices in China[58]. Corporate Governance and Shareholder Relations - The company’s board of directors must approve any share repurchase plan, which must be completed within 30 trading days after the resolution is passed[187]. - The company has established a clear framework for share repurchase and stabilization, ensuring transparency and adherence to regulatory requirements[186]. - The company has committed to not selling shares acquired under the buyback plan for six months after completion[188]. - The company has a history of consistent cash dividends, with the 2020 cash dividend representing 32.50% of the net profit attributable to ordinary shareholders[185].

Financial Performance - The company's revenue for Q1 2021 was ¥102,316,781.63, representing a 175.44% increase compared to ¥37,146,726.16 in the same period last year[8] - Net profit attributable to shareholders was ¥19,258,855.13, up 117.06% from ¥8,872,599.72 year-on-year[8] - The net profit after deducting non-recurring gains and losses reached ¥18,778,459.93, a significant increase of 390.58% compared to ¥3,827,824.95 in the previous year[8] - The basic earnings per share for the period was ¥0.1833, reflecting a 116.92% increase from ¥0.0845 in the same quarter last year[8] - The company achieved operating revenue of ¥102,316,781.63, a year-on-year increase of 175.44% due to the resumption of business activities after COVID-19 disruptions[19] - Net profit attributable to shareholders reached ¥19,258,855.13, up 117.06% compared to the same period last year[19] - The company reported a net profit of ¥270,991,040.43 as of March 31, 2021, compared to ¥254,775,601.57 at the end of 2020, indicating an increase of about 6.5%[45] - The company reported a total comprehensive income of ¥19,691,763.50, up from ¥8,872,599.72 in the previous period, indicating a growth of approximately 121%[49] Assets and Liabilities - The company's total assets at the end of the reporting period were ¥815,484,780.95, a decrease of 1.42% from ¥827,239,473.77 at the end of the previous year[8] - Current assets totaled ¥494,845,679.01, down from ¥523,295,787.76, indicating a decrease of about 5.4%[40] - Cash and cash equivalents decreased to ¥270,169,579.52 from ¥388,558,373.95, representing a decline of approximately 30.4%[40] - Accounts receivable increased to ¥88,045,709.59 from ¥79,228,290.34, showing an increase of about 11.5%[40] - Total current liabilities decreased to ¥46,716,755.05 from ¥85,238,417.14, a reduction of approximately 45.1%[41] - Total non-current liabilities rose to ¥5,892,537.52 from ¥2,160,861.74, an increase of about 172.5%[41] - The company's equity attributable to shareholders increased to ¥762,072,392.50 from ¥739,520,007.37, reflecting a growth of approximately 3.0%[42] - Total assets amounted to CNY 827,239,473.77, a slight decrease from CNY 831,279,623.68[62] Cash Flow - The net cash flow from operating activities was negative at -¥45,806,338.66, worsening by 98.53% compared to -¥23,073,185.78 in the same period last year[8] - Cash inflows from operating activities totaled ¥87,888,057.81, compared to ¥53,867,919.21 in the previous period, representing an increase of about 63.1%[53] - The net cash flow from operating activities was -45,806,338.66 CNY, compared to -23,073,185.78 CNY in the previous period, indicating a decline in operational cash generation[54] - Total cash outflow from operating activities amounted to 133,694,396.47 CNY, up from 76,941,104.99 CNY year-over-year[54] - The net cash flow from investing activities was -72,486,370.77 CNY, compared to -29,134,619.46 CNY in the previous period, reflecting increased investment expenditures[54] - Cash and cash equivalents at the end of the period were 270,169,579.52 CNY, down from 368,432,661.91 CNY in the previous year[55] Research and Development - The company’s R&D expenses increased by 34.70% to ¥5,755,136.68, reflecting a recovery in R&D activities after pandemic-related disruptions[18] - The company launched new products, including an anesthesia depth monitor and disposable non-invasive EEG sensors, contributing to new revenue growth[19] - The company obtained 4 invention patents, 1 utility model patent, and 6 design patents during the reporting period, enhancing its intellectual property portfolio[22] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 9,503[11] - The largest shareholder, Wang Ningyu, holds 36.15% of the shares, with 9,849,800 shares pledged[11] - A total of 497.25 million restricted shares were granted to 250 incentive recipients during the first extraordinary shareholders' meeting of 2021[26] Investments and Collaborations - The company has allocated CNY 5,818.1 million (37.39%) for the industrial base upgrade project, with CNY 1,200.28 million invested to date[29] - The R&D center construction project has received CNY 2,264.25 million (21.10%) of its CNY 10,732.61 million budget, with CNY 457.8 million invested so far[29] - The company is collaborating with the University of Sydney's China Center to develop edge intelligence analysis algorithms for pain detection in anesthesia devices[24] - The company invested CNY 25 million in Tianfeng Capital equity investment fund to explore quality projects in the industry[26] Compliance and Audit - As of March 31, 2021, the company has not experienced any overdue commitments from major stakeholders[27] - The company has not reported any non-compliance issues regarding external guarantees during the reporting period[32] - The company has not undergone an audit for the first quarter report[68]

江苏爱朋医疗科技股份有限公司 2020 年第三季度报告全文 江苏爱朋医疗科技股份有限公司 2020 年第三季度报告 2020 年 10 月 - 1 - 江苏爱朋医疗科技股份有限公司 2020 年第三季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人王凝宇、主管会计工作负责人袁栋麒及会计机构负责人（会计 主管人员）施燕飞声明：保证季度报告中财务报表的真实、准确、完整。 - 2 - 江苏爱朋医疗科技股份有限公司 2020 年第三季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期末 | 上年度末 | 本报告期末比上年度末增减 | | | --- | --- | --- | --- | --- | | 总资产（元） | 767,997,929.23 | 757,642,068.05 | | 1.37% | | 归属于上市公司股东的净资产（元） ...

Financial Performance - The company reported a revenue of RMB 100 million for the first half of 2020, representing a year-on-year increase of 15%[1]. - The company's operating revenue for the reporting period was CNY 134,412,661.76, a decrease of 20.59% compared to the same period last year[19]. - Net profit attributable to shareholders was CNY 32,839,054.88, down 20.32% year-on-year[19]. - The total comprehensive income for the first half of 2020 was CNY 32,839,054.88, down from CNY 41,555,742.56 in the same period of 2019[180]. - Basic earnings per share for the first half of 2020 was CNY 0.31, down from CNY 0.39 in the first half of 2019[180]. - The company achieved total revenue of 134.41 million yuan, a decrease of 20.59% year-on-year[63]. - The net cash flow from operating activities was negative CNY 36,502,746.62, a decline of 330.14% compared to the previous year[19]. - The company reported a significant increase in cash received from other operating activities, rising to CNY 9,145,220.56 from CNY 1,052,967.01 in 2019[185]. Assets and Liabilities - The total assets of the company reached RMB 500 million as of June 30, 2020, showing a growth of 10% compared to the end of 2019[1]. - The total assets at the end of the reporting period were CNY 742,372,876.28, a decrease of 2.02% from the end of the previous year[19]. - The company's current assets totaled CNY 505,076,084.38, down from CNY 539,475,094.90 at the end of 2019, reflecting a decline of approximately 6.4%[172]. - Cash and cash equivalents decreased significantly from CNY 420,591,393.37 at the end of 2019 to CNY 223,077,874.83, a drop of about 47%[171]. - Accounts receivable increased to CNY 79,562,838.57 from CNY 50,752,234.41, representing a growth of approximately 56.9%[171]. - The company's total liabilities decreased from CNY 82,760,643.09 to CNY 66,972,396.44, a reduction of about 19.1%[173]. Research and Development - The company plans to invest RMB 20 million in research and development for new pain management technologies in the upcoming year[1]. - The company’s R&D team has been granted 67 patents and 37 software copyrights, demonstrating strong innovation capabilities[57]. - The company has developed a high-precision intelligent microcomputer infusion pump and a wireless pain management system for acute pain management[27]. - The company is focused on expanding its product line with innovative medical devices to enhance patient care[70]. - The company has made significant progress in its key R&D projects, with the intelligent and information-based drug delivery device currently undergoing registration testing[72]. Market Strategy and Expansion - The company is focusing on expanding its market presence in Southeast Asia, aiming for a 30% increase in sales in that region by the end of 2021[1]. - The company aims to establish a comprehensive ecosystem in pain management and nasal care over the next five years[26]. - The company aims to expand its market presence through academic collaboration and public education, enhancing brand recognition in the nasal care sector[56]. - The company plans to extend its product reach from hospital treatments to self-care solutions through retail and online channels[52]. - The company is enhancing its information systems to improve real-time feedback and efficiency for clinical staff[72]. Product Development and Innovation - The company has launched a new wireless pain management system, which is expected to contribute an additional RMB 10 million in revenue by the end of 2020[1]. - The iPainfree™ wireless pain management system software provides comprehensive pain management tools, enhancing pain assessment and monitoring capabilities for healthcare professionals[29]. - The company has developed the iPainfree™ obstetric pain management information system, filling a gap in the market for labor pain management solutions, and improving medical quality and safety during perinatal care[30]. - The company is working on a centralized monitoring system for postoperative pain management, which is currently in clinical trial preparation[73]. - The company is developing a new type of infusion device consumable that is compatible with all current driving devices, with project planning completed[73]. Financial Management - The company has no plans to distribute cash dividends or issue bonus shares for the current fiscal year[1]. - The company reported a financial income of CNY 4,659,205.05, significantly higher than CNY 613,149.61 in the previous year[179]. - The company has established three special accounts for raised funds, with balances in various banks totaling RMB 67.51 million[97]. - The company has a clear management method for raised funds, ensuring compliance with relevant laws and regulations[96]. - The company has not engaged in any derivative investments or entrusted loans during the reporting period[106][107]. Operational Efficiency - The production department organizes and executes annual production plans based on sales forecasts and inventory levels to ensure timely delivery of products[38]. - The company emphasizes strict procurement management and quality control processes to ensure the reliability of raw materials used in production[37]. - The company aims to improve operational efficiency and reduce costs through the adoption of remote office and online promotion methods[100]. - The company has passed multiple quality management system certifications, including ISO9001 and ISO13485[59]. - The company has not reported any failures in registration certificates during the reporting period[70]. Market Trends and Insights - The current pain management market is driven by a growing number of surgical procedures, with postoperative pain management remaining a dominant segment in the company's sales[44]. - The cancer pain management market is expanding, with approximately 25% of newly diagnosed cancer patients experiencing pain, and the incidence in late-stage patients reaching 60%-80%[45]. - The prevalence of allergic rhinitis in China is approximately 17.6%, with chronic sinusitis at about 8%, indicating a significant market for nasal care products[49]. - The promotion of painless childbirth is supported by the establishment of 913 hospitals as pilot sites, which will directly boost sales of related products[42]. - The pain management and nasal care medical device markets are in their early development stages but have significant growth potential[43].

Financial Performance - Total revenue for Q1 2020 was ¥37,146,726.16, a decrease of 46.67% compared to ¥69,655,092.77 in the same period last year[8] - Net profit attributable to shareholders was ¥8,872,599.72, down 41.82% from ¥15,250,873.36 year-on-year[8] - Net profit after deducting non-recurring gains and losses was ¥3,827,824.95, a significant decline of 72.46% compared to ¥13,899,130.35 in the previous year[8] - Basic and diluted earnings per share were both ¥0.11, down 42.11% from ¥0.19 in the previous year[8] - Total operating revenue for Q1 2020 was CNY 37,146,726.16, a decrease of 46.3% compared to CNY 69,655,092.77 in Q1 2019[37] - Net profit for Q1 2020 was CNY 8,872,599.72, down 42.3% from CNY 15,336,376.79 in Q1 2019[39] - Total profit for Q1 2020 was CNY 11,690,862.53, down 35.5% from CNY 18,110,593.14 in Q1 2019[39] Cash Flow - The net cash flow from operating activities was -¥23,073,185.78, worsening by 49.58% from -¥15,424,999.55 in the same period last year[8] - Cash inflow from operating activities was CNY 53,867,919.21, a decrease of 17.7% compared to CNY 65,421,482.02 in the same period last year[43] - The total cash outflow from investing activities was ¥61,288,011.24, significantly higher than ¥420,983,266.77 in the previous year, resulting in a net cash flow from investing activities of -¥29,134,619.46[44] - The company experienced a net decrease in cash and cash equivalents of -¥52,207,805.24 in Q1 2020, compared to -¥367,268,847.17 in the same period last year[45] - Cash and cash equivalents at the end of Q1 2020 stood at ¥368,432,661.91, down from ¥436,837,220.68 at the beginning of the quarter[45] Assets and Liabilities - Total assets at the end of the reporting period were ¥735,399,937.81, a decrease of 2.94% from ¥757,642,068.05 at the end of the previous year[8] - Total liabilities decreased to CNY 51,645,913.13 from CNY 82,760,643.09, reflecting a reduction of 37.6%[31] - Current liabilities totaled CNY 49,139,856.01, a significant drop from CNY 80,268,318.11 in the previous period[31] - The total current assets as of March 31, 2020, amounted to 509.02 million RMB, down from 539.48 million RMB at the end of 2019, a decrease of approximately 5.6%[29] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 10,099[11] - The largest shareholder, Wang Ningyu, holds 36.15% of the shares, with 5,000,000 shares pledged[11] - Net assets attributable to shareholders increased by 1.31% to ¥683,754,024.68 from ¥674,881,424.96 at the end of the previous year[8] Operational Challenges - The company faced operational challenges due to the COVID-19 pandemic, delaying the resumption of work until February 17, 2020[17] - The marketing network construction project was not implemented as planned due to changes in market and policy environments post-IPO[22] Investments and Future Plans - The company is actively preparing to establish a business platform and set up an angel fund to enhance its service capabilities in the medical device sector[18] - The total amount of committed investment projects is 26,293 million RMB, with a cumulative benefit of 4,286.35 million RMB[22] - The company plans to use idle funds of up to 230 million RMB for cash management, ensuring no impact on normal operations[23] Research and Development - Research and development expenses for Q1 2020 were CNY 4,272,535.29, down 15.2% from CNY 5,038,018.66 in Q1 2019[40] - Jiangsu Aipeng Medical Technology Co., Ltd. is focusing on expanding its market presence and enhancing its product offerings through ongoing research and development initiatives[48] Compliance and Standards - The company has not reported any non-operating fund occupation by controlling shareholders during the reporting period[25] - The company has not experienced any violations regarding external guarantees during the reporting period[24] - The company implemented new revenue and lease standards starting in 2020, affecting prior comparative data[57]

Financial Performance - The company's operating revenue for 2019 was CNY 379,647,097.53, representing a 27.38% increase compared to CNY 298,033,812.31 in 2018[17]. - The net profit attributable to shareholders for 2019 was CNY 102,343,469.80, a 46.02% increase from CNY 70,089,798.68 in the previous year[17]. - The net profit after deducting non-recurring gains and losses was CNY 84,541,753.95, up 26.35% from CNY 66,909,349.89 in 2018[17]. - The basic earnings per share for 2019 was CNY 1.27, an increase of 9.48% from CNY 1.16 in 2018[17]. - The total assets at the end of 2019 were CNY 757,642,068.05, a 10.13% increase from CNY 687,955,326.39 at the end of 2018[17]. - The net assets attributable to shareholders at the end of 2019 were CNY 674,881,424.96, an increase of 11.58% from CNY 604,857,955.16 in 2018[17]. - The company reported a net cash flow from operating activities of CNY 77,590,761.60, a slight decrease of 0.69% compared to CNY 78,127,068.21 in 2018[17]. - The company achieved total revenue of CNY 379.65 million, a year-on-year increase of 27.38%[48]. - Net profit attributable to shareholders reached CNY 102.34 million, up 46.02% compared to the previous year[48]. - The company recorded a gross profit margin of 70.49% for 2019, which is a decrease of 6.01% compared to the previous year[105]. Dividend Distribution - The company reported a profit distribution plan to distribute a cash dividend of 4 RMB per 10 shares to all shareholders, based on 80,800,000 shares[5]. - The cash dividend distribution represents 31.58% of the net profit attributable to ordinary shareholders for 2019, which is RMB 102,343,469.80[171]. - The company has a profit distribution plan for 2019 that includes no stock dividends, with a capital reserve increase of 3 shares for every 10 shares held[169]. - The company has a history of consistent cash dividend payments, with the same amount distributed in 2018 as in 2019[170]. - The company has accumulated distributable profits of RMB 20,668.12 million as of December 31, 2019[169]. Business Strategy and Market Focus - The company has subsidiaries involved in various sectors, including medical devices and biotechnology, indicating a diversified business model[10]. - The company aims to enhance shareholder value through strategic initiatives and market expansion efforts[5]. - The company is focused on pain management solutions, which include various methods for pain assessment and treatment[10]. - The company has a commitment to innovation in medical technology, as indicated by its ongoing research and development efforts[10]. - The company aims to become the leading brand in intelligent medical devices for pain management and nasal care within the next five years[25]. - The company is focusing on a one-stop medical device innovation incubation platform, providing full lifecycle solutions from product development to market launch[47]. - The company aims to expand its nasal care product sales channels from hospitals to retail and online platforms, enhancing brand visibility and accessibility[64]. - The company is focused on expanding its market presence in the medical device sector through strategic investments and partnerships[130]. Research and Development - The company invested 24.5 million CNY in R&D, a year-on-year increase of 16.75%, supported by a 93-member R&D team[89]. - The company is committed to enhancing its research and development capabilities by focusing on market demand and technological trends, aiming to maintain industry leadership[160]. - R&D efforts will focus on pain management and nasal care, with plans to develop new medical devices and enhance existing products[155]. - The company has established a comprehensive quality control system covering all stages from R&D to after-sales[75]. - The company has implemented strict quality management systems to mitigate risks associated with product quality control across various operational stages[162]. Market Presence and Sales - The pain management product segment generated revenue of 249.15 million yuan, accounting for 65.63% of total revenue, with a year-on-year growth of 15.76%[80]. - The microcomputer infusion pump generated revenue of 221.29 million yuan, reflecting a year-on-year increase of 20.53%[80]. - The company's pain management products are recognized in 1,500 medical institutions across 273 cities, including 1,417 public hospitals[80]. - The nasal care product line includes "Nose Clean" saline nasal spray and has established a robust sales network through various channels[82]. - The company has established partnerships with over 600 hospitals for painless childbirth services, with more than 400 hospitals collaborating on pilot projects as per the national guidelines[32]. Risk Management and Compliance - The company emphasizes the importance of risk awareness regarding future plans and development strategies, highlighting potential discrepancies between plans, forecasts, and commitments[5]. - The company has no significant discrepancies between financial reports prepared under international and Chinese accounting standards[20]. - The company has maintained compliance with its commitments to minority shareholders throughout the reporting period[177]. - The company’s financial report did not receive a non-standard audit report, indicating a clean audit opinion[179]. - The company has taken measures to mitigate the impact of share dilution from its fundraising activities[180]. Corporate Governance - The company strictly fulfilled the commitment not to transfer or entrust the management of shares held directly or indirectly for 36 months from the date of stock listing[172]. - The controlling shareholder and actual controller committed to not reducing their holdings for two years after the lock-up period, with a maximum reduction of 5% of the total share capital post-IPO[173]. - The company has established a clear framework for managing share reductions and stabilizing stock prices in response to market conditions[173]. - The company will notify three trading days in advance before any planned share reduction by major shareholders[173]. - The company has committed to ensuring that its prospectus and other disclosure materials do not contain false records or misleading statements[175].

2019 年第三季度报告 2019 年 10 月 - 1 - 江苏爱朋医疗科技股份有限公司 2019 年第三季度报告全文 江苏爱朋医疗科技股份有限公司 江苏爱朋医疗科技股份有限公司 2019 年第三季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人王凝宇、主管会计工作负责人袁栋麒及会计机构负责人(会计主 管人员)秦敏声明：保证季度报告中财务报表的真实、准确、完整。 - 2 - 江苏爱朋医疗科技股份有限公司 2019 年第三季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期末 | 上年度末 | 本报告期末比上年度末增减 | | | --- | --- | --- | --- | --- | | 总资产（元） | 708,059,123.94 | 687,955,326.39 | | 2.92% | | 归属于上市公司股东的净资产（元） ...

Financial Performance - The company reported a revenue of RMB 100 million for the first half of 2019, representing a year-on-year increase of 20%[3]. - Total revenue for the reporting period reached ¥169,271,532.03, an increase of 28.57% compared to ¥131,661,146.69 in the same period last year[19]. - Net profit attributable to shareholders was ¥41,212,789.06, reflecting a growth of 23.81% from ¥33,287,292.64 year-on-year[19]. - The company has set a revenue target of RMB 200 million for the full year 2019, which would require a 25% growth in the second half[3]. - The company achieved total operating revenue of 169.27 million yuan, an increase of 28.57% compared to the same period last year[37]. - The net profit attributable to shareholders of the listed company was 41.21 million yuan, up 23.81% year-on-year[37]. - The net profit after deducting non-recurring gains and losses was 37.84 million yuan, reflecting a growth of 20.11% year-on-year[37]. - The company reported a net profit for the first half of 2019 of CNY 41,555,742.56, representing a growth of 23.1% from CNY 33,756,884.28 in the previous year[171]. Research and Development - The company plans to invest RMB 30 million in R&D for new product development in the next fiscal year[3]. - The company invested CNY 10.79 million in R&D, representing 6.37% of total revenue, with a year-on-year growth of 7.01%[70]. - Research and development expenses increased to CNY 10,786,471.43, compared to CNY 10,079,649.76 in the first half of 2018, reflecting a focus on innovation[171]. - The company is developing an intelligent, information-based precise drug delivery device with several innovative features[71]. - The new product development includes a microcomputer electric infusion pump and a wearable heart rhythm monitoring device, with testing and registration processes ongoing[73]. Market Expansion and Strategy - The company is expanding its market presence in Southeast Asia, aiming for a 10% market share by the end of 2020[3]. - User data indicates a 15% increase in the number of active users of the company's medical devices compared to the previous year[3]. - The company is focusing on three target segments in pain management: postoperative pain, labor pain, and cancer pain[61]. - The company is actively participating in academic conferences to enhance brand recognition and product awareness among medical professionals[69]. - The company has established a comprehensive sales network covering hospitals, pharmacies, and e-commerce platforms for nasal care products[67]. Product Development and Portfolio - A new pain management product is expected to launch in Q4 2019, projected to contribute an additional RMB 20 million in revenue[3]. - The company specializes in pain management and nasal care medical devices, aiming to become a leader in "comfortable medical intelligent hardware" in the industry[27]. - Key products in pain management include microcomputer infusion pumps and wireless pain management systems, which enhance patient care and reduce medical errors[28]. - The nasal care product line includes various nasal spray devices and saline solutions, addressing issues like nasal dryness and congestion[31]. - The company is developing a standardized platform tool to achieve seamless information connection between various medical information systems, improving clinical efficiency[72]. Financial Position and Assets - Total assets at the end of the reporting period were ¥679,902,207.94, a decrease of 1.17% from ¥687,955,326.39 at the end of the previous year[19]. - The net assets attributable to shareholders increased by 1.47% to ¥613,750,744.22, compared to ¥604,857,955.16 at the end of the previous year[19]. - The company’s total assets have seen a significant increase in construction projects by 45.10%, primarily due to the development of the Aipeng Medical Industrial Park[55]. - Cash and cash equivalents decreased by 83.35%, attributed to the investment of idle funds in bank financial products[55]. - The company reported a significant increase in other current assets from CNY 1,187,056.67 to CNY 303,420,091.93, a growth of approximately 25,487.5%[161]. Risks and Challenges - The company faces risks related to regulatory changes and market competition, which it is actively monitoring[5]. - The company is facing risks related to industry policies, which may impact its competitive advantage and operational performance[111]. - The company has implemented strict quality control measures to mitigate risks associated with product safety and effectiveness[113]. Shareholder Information - The total number of shares is 80,800,000, with 75.00% being restricted shares and 25.00% being unrestricted shares[141]. - The largest shareholder, Wang Ningyu, holds 36.15% (29,210,135 shares) of the total shares, which are pledged[143]. - The company has not experienced any changes in its controlling shareholder or actual controller during the reporting period[145][146]. - The company plans not to distribute cash dividends or issue bonus shares for the half-year period[116]. Quality Control and Certifications - The company has established a supplier database and conducts annual evaluations of selected suppliers to ensure quality control in raw material procurement[34]. - The company has received various quality management certifications, including ISO 9001 and ISO 13485, ensuring high product quality and safety standards[58]. - The company has implemented a comprehensive quality control system covering all aspects from R&D to after-sales, ensuring product quality and compliance[74].

Financial Performance - Total revenue for Q1 2019 reached ¥69,655,092.77, an increase of 28.38% compared to ¥54,257,272.52 in the same period last year[8] - Net profit attributable to shareholders was ¥15,250,873.36, reflecting a growth of 28.72% from ¥11,847,911.98 year-over-year[8] - Net profit excluding non-recurring gains and losses was ¥13,899,130.35, up 21.35% from ¥11,453,944.13 in the previous year[8] - Basic earnings per share decreased by 5.00% to ¥0.19 from ¥0.20 year-over-year[8] - The total profit for the period was CNY 18.11 million, up 30.73% year-on-year, while net profit attributable to shareholders reached CNY 15.25 million, an increase of 28.72%[19] - Total operating revenue for Q1 2019 reached ¥69,655,092.77, a 28.4% increase from ¥54,257,272.52 in the same period last year[42] - Net profit for Q1 2019 was ¥15,336,376.79, representing a 28.5% increase compared to ¥11,896,645.18 in Q1 2018[43] - Total comprehensive income for the first quarter was CNY 14,541,201.02, compared to CNY 9,566,986.13 in the previous year, representing an increase of approximately 52.1%[48] Cash Flow - The net cash flow from operating activities was -¥15,424,999.55, a decline of 17.60% compared to -¥13,116,907.46 in the same period last year[8] - Cash inflow from operating activities totaled CNY 65,421,482.02, up from CNY 57,323,165.23, marking an increase of about 14.6%[51] - Net cash flow from operating activities was negative at CNY -15,424,999.55, worsening from CNY -13,116,907.46 in the previous year[51] - Cash inflow from investment activities was CNY 70,317,031.75, significantly higher than CNY 5,000.00 in the previous year[52] - Net cash flow from investment activities was negative at CNY -350,666,235.02, compared to CNY -24,822,908.64 in the previous year, indicating a substantial increase in cash outflows[52] - The ending balance of cash and cash equivalents decreased to CNY 69,568,373.51 from CNY 131,728,634.07, a decline of approximately 47.3%[52] - The company reported a net cash outflow from financing activities of CNY -1,086,719.37, with no cash inflow recorded during the period[56] Assets and Liabilities - Total assets at the end of the reporting period were ¥679,254,196.16, down 1.26% from ¥687,955,326.39 at the end of the previous year[8] - Total current assets decreased to CNY 503,994,495.64 from CNY 517,884,817.76, a decline of approximately 2.3%[34] - Total liabilities decreased to CNY 50,522,820.33 from CNY 74,560,327.35, a reduction of approximately 32.3%[35] - The company's total liabilities decreased to ¥39,742,626.93 from ¥54,093,032.16 year-on-year[41] - The total current liabilities decreased to CNY 47,821,586.99 from CNY 71,937,958.95, a decline of approximately 33.5%[35] - The company reported a significant reduction in employee compensation payable, decreasing to CNY 7,267,358.25 from CNY 18,405,360.31, a drop of about 60.5%[35] Research and Development - Research and development expenses amounted to CNY 5.04 million, a 14.85% increase from the previous year, accounting for 7.23% of operating revenue[19] - The company is advancing key R&D projects, including a medical peristaltic pump, which has entered the chemical research phase, and an information system shared service platform, now in the verification stage[20] - Research and development expenses for Q1 2019 were ¥5,038,018.66, an increase from ¥4,386,439.04 in Q1 2018[42] Market and Strategy - The pain management segment saw significant growth, with revenue of CNY 53.28 million, a 28.80% increase year-on-year, driven by market expansion and strong technical foundation[19] - The company effectively executed its development strategy and 2019 operational plan, focusing on pain management and nasal care markets[23] - The company plans to enhance product quality and respond proactively to market changes to improve overall competitiveness[23] Shareholder Information - The total number of shareholders at the end of the reporting period was 11,757[12] - The company reported non-recurring gains totaling ¥1,351,743.01 for the period[9] - The company has not encountered any significant risk factors or operational difficulties during the reporting period[23] - There were no overdue commitments from actual controllers, shareholders, or related parties during the reporting period[23] - There were no violations regarding external guarantees during the reporting period[29] - The company reported no non-operating fund occupation by controlling shareholders or related parties[29]

Financial Performance - The company's operating revenue for 2018 was CNY 298,033,812.31, representing a 20.70% increase compared to CNY 246,922,317.24 in 2017[18]. - The net profit attributable to shareholders for 2018 was CNY 70,089,798.68, up 21.01% from CNY 57,921,514.33 in 2017[18]. - The net profit after deducting non-recurring gains and losses was CNY 66,909,349.89, reflecting a 20.50% increase from CNY 55,527,932.91 in 2017[18]. - The net cash flow from operating activities for 2018 was CNY 78,127,068.21, an increase of 16.48% compared to CNY 67,075,966.07 in 2017[18]. - The total assets at the end of 2018 reached CNY 687,955,326.39, a significant increase of 106.44% from CNY 333,255,051.54 at the end of 2017[18]. - The net assets attributable to shareholders at the end of 2018 were CNY 604,857,955.16, up 122.51% from CNY 271,838,132.81 at the end of 2017[18]. - The basic earnings per share for 2018 were CNY 1.16, a 20.83% increase from CNY 0.96 in 2017[18]. - The diluted earnings per share for 2018 were also CNY 1.16, reflecting the same growth of 20.83% compared to CNY 0.96 in 2017[18]. - The weighted average return on equity for 2018 was 22.84%, a slight decrease of 0.77% from 23.61% in 2017[18]. - The company reported a loss from the disposal of non-current assets of CNY 50,922.59 in 2018, compared to a loss of CNY 9,231.60 in 2017[24]. Research and Development - The report outlines the company's commitment to research and development in new products and technologies within the medical field[10]. - The company achieved a research and development investment of RMB 20.98 million in 2018, representing a 4.78% increase year-over-year, and accounting for 7.04% of the annual revenue[50]. - The company has maintained a consistent focus on R&D and product innovation to enhance its market position in the medical device industry[28]. - The company holds 63 patents, including 6 invention patents, and has established a strong R&D capability recognized as a high-tech enterprise by Jiangsu Province[50]. - The company is focusing on three target segments in pain management: postoperative analgesia, labor analgesia, and tumor analgesia[101]. - The company is committed to developing a leading brand in pain management and nasal care medical devices through continuous technological innovation and high-quality service[97]. Market Strategy and Expansion - The company is focused on market expansion and strategic acquisitions to enhance its competitive position in the healthcare industry[10]. - The company expanded its market presence by adding 263 new distributors and 296 new terminal hospitals, including 91 tertiary hospitals, during the reporting period[52]. - The company is actively developing online sales channels for its nasal care products, utilizing internet marketing strategies to enhance brand recognition[55]. - The company aims to expand its market presence by establishing regional marketing centers in 20 key cities, including Beijing and Guangzhou[162]. - Future product development will focus on pain management systems and nasal care products, leveraging new technologies such as AI and medical information systems[159]. Corporate Governance and Compliance - The report emphasizes the importance of risk awareness regarding future plans and development strategies, indicating potential discrepancies between plans, forecasts, and commitments[5]. - The company has confirmed that all board members attended the meeting to review the annual report, ensuring accountability for the report's accuracy[4]. - The financial report is guaranteed to be true, accurate, and complete by the company's responsible personnel, including the chairman and accounting manager[4]. - The company is committed to improving corporate governance and transparency in accordance with relevant laws and regulations[112]. - The company has established a mechanism to strengthen investor returns and ensure the proper use of raised funds[183]. Product Development and Innovation - The company launched a new product, the "Sensitive Companion Probiotic Powder Solid Beverage," during the reporting period[38]. - The company launched a high-osmotic buffered seawater nasal care spray, achieving positive market results[108]. - The company is focusing on the development of new products, including a portable electric infusion pump and a multi-channel pediatric brain oxygen monitoring system[106]. - The company has developed various software for its medical devices, enhancing its product offerings[85]. Shareholder and Stock Management - The company plans to distribute a cash dividend of 4.00 RMB per 10 shares to all shareholders, based on a total of 80,800,000 shares[5]. - The company strictly adhered to the lock-up commitments for shareholders, ensuring no transfer or management of shares for 36 months post-IPO[179]. - Shareholders are restricted from reducing their holdings for two years after the lock-up period, with a maximum reduction of 5% of the total share capital post-IPO[180]. - The company will implement measures to stabilize stock prices if the average stock price falls below the latest audited net asset value per share for 20 consecutive trading days[180]. - The company plans to repurchase shares to stabilize stock prices, adhering to relevant laws and regulations[180]. Financial Structure and Investment - The company aims to optimize its financial structure by utilizing low-risk investments to improve capital efficiency and returns, while also considering bank loans or capital market financing as needed[166]. - The company will increase R&D investment to enhance its independent innovation capabilities and improve the conversion of R&D results into production[169]. - The company reported a significant increase in monetary funds due to the IPO, with cash reserves rising by ¥266,319,682.67[144]. - The company has not utilized any of the raised funds from the IPO as of the end of 2018, with a balance of ¥264,081,035.29 remaining[150].